Clinical Trial Update: Leptin to Treat Severe Insulin Resistance - Pilot Study [Phase 2]

View source ↗

Summary

A Phase 2 pilot trial sponsored by NIDDK tested metreleptin (leptin) for treating severe insulin resistance; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Resistance

Drugs mentioned

• Metreleptin (Myalept) (metreleptin)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Syndrome | Phase 2 | Status: COMPLETED